Outcome of children and adolescents with central nervous system tumors in phase I trials
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-017-2698-z
Abstract: Central nervous system (CNS) tumors are a leading cause of death in pediatric oncology. New drugs are desperately needed to improve survival. We evaluated the outcome of children and adolescents with CNS tumors participating in… read more here.
Keywords: nervous system; central nervous; cns tumors; phase trials ... See more keywords
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2019.07.007
Abstract: Quality of life (QoL) is not included among the end points in many studies, and QoL results are underreported in many phase 3 oncology trials. We performed a systematic review to describe QoL prevalence and… read more here.
Keywords: phase trials; qol; cancer; prostate cancer ... See more keywords
A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2021.102300
Abstract: BACKGROUND A high number of combinations of PD-1/PD-L1 inhibitors with other anti-cancer therapies are in clinical development. The usefulness of phase II trials in evaluating their efficacy and safety is unclear. MATERIALS AND METHODS We… read more here.
Keywords: phase; exploring anti; review phase; systematic review ... See more keywords
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.07.027
Abstract: INTRODUCTION Life expectancy evaluation is crucial when selecting patients who may benefit from phase I studies. The Royal Marsden Hospital (RMH) prognostic score, based on three objective variables (number of metastatic sites, lactate dehydrogenase (LDH)… read more here.
Keywords: phase; prognostic score; validation; cohort ... See more keywords
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.06.003
Abstract: BACKGROUND Adolescent and young adult (AYA) patients with advanced solid tumours are often considered for phase I clinical trials with novel agents. The outcome of AYAs in these trials have not been described before. AIM… read more here.
Keywords: advanced solid; aya patients; phase trials; cancer ... See more keywords
Early phase trials of novel hearing therapeutics: Avenues and opportunities
Sign Up to like & getrecommendations! Published in 2019 at "Hearing Research"
DOI: 10.1016/j.heares.2019.07.003
Abstract: Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation… read more here.
Keywords: trials novel; early phase; therapeutics avenues; hearing therapeutics ... See more keywords
Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes.
Sign Up to like & getrecommendations! Published in 2019 at "Canadian journal of diabetes"
DOI: 10.1016/j.jcjd.2018.05.008
Abstract: Guidelines increasingly highlight the importance of multifactorial management in type 2 diabetes, in contrast to the more traditional focus on glycemic control. Semaglutide, a recently approved glucagon-like peptide-1 receptor agonist, is indicated in Canada for… read more here.
Keywords: diabetes semaglutide; type diabetes; phase trials; place ... See more keywords
Investigational drugs in phase II clinical trials for acute coronary syndromes
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2020.1708324
Abstract: ABSTRACT Introduction: Despite current guideline-based, secondary prevention strategies in patients with the acute coronary syndrome, the residual ischemic risk is still at an unacceptable rate, and there is a concomitant high bleeding event rate. These… read more here.
Keywords: investigational drugs; acute coronary; phase trials; phase clinical ... See more keywords
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2022.2158811
Abstract: ABSTRACT Introduction Current antipsychotics are postsynaptic dopamine-2(D2) receptor blockers, which often, but not always, effectively improve acute psychotic symptoms and prevent relapse in schizophrenia and other severe mental disorders, but are associated with various side… read more here.
Keywords: treatment schizophrenia; phase trials; treatment; schizophrenia ... See more keywords
Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2018.1481390
Abstract: ABSTRACT Introduction: Neuroprotection and remyelination are two unmet needs in the treatment of multiple sclerosis (MS). Therapeutic potential has been identified with sexual hormones, supported in women by a decrease in MS activity during the… read more here.
Keywords: effect; multiple sclerosis; effect testosterone; phase trials ... See more keywords
NIMG-47. VOLUMETRIC ANALYSIS OF PHASE 2 AND 3 TRIALS IN RECURRENT GLIOBLASTOMA TREATED WITH VB-111 WITH OR WITHOUT BEVACIZUMAB OR BEVACIZUMAB MONOTHERAPY
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.717
Abstract: VB-111 is a non-replicating adenovirus carrying a pro-apoptotic transgene for TNFR1/Fas under the control of a modified murine promoter to pre-proendothelin 1. The transgene is expressed only in angiogenic endothelial cells, and therefore VB-111 results… read more here.
Keywords: combination; phase; bevacizumab; phase trials ... See more keywords